Login to Your Account

Inspire's Stock Falls 44 Percent On Missed Diquafosol Endpoint

By Karen Pihl-Carey

Thursday, February 10, 2005
While diquafosol tetrasodium failed to hit the primary endpoint in a Phase III trial for dry eye disease, Inspire Pharmaceuticals Inc. plans to file a new drug application amendment by the end of the second quarter. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription